Digestive and Liver Disease Supplements最新文献

筛选

英文中文

Efficacy of butyrate in the treatment of mild to moderate Crohn's disease 丁酸盐治疗轻至中度克罗恩病的疗效观察

Digestive and Liver Disease Supplements Pub Date : 2007-09-01 DOI: 10.1016/S1594-5804(08)60009-1

A. Di Sabatino, P. Cazzola, R. Ciccocioppo, R. Morera, P. Biancheri, L. Rovedatti, L. Cantoro, A. Vanoli, F.P. Tinozzi, S. Tinozzi, G.R. Corazza

{"title":"Efficacy of butyrate in the treatment of mild to moderate Crohn's disease","authors":"A. Di Sabatino, P. Cazzola, R. Ciccocioppo, R. Morera, P. Biancheri, L. Rovedatti, L. Cantoro, A. Vanoli, F.P. Tinozzi, S. Tinozzi, G.R. Corazza","doi":"10.1016/S1594-5804(08)60009-1","DOIUrl":"10.1016/S1594-5804(08)60009-1","url":null,"abstract":"<div><h3>Background</h3><p>Butyrate exerts anti-inflammatory effects in experimental colitis and in lamina propria mononuclear cells of patients with Crohn's disease.</p></div><div><h3>Aims</h3><p>To assess the safety and efficacy of butyrate in Crohn's disease.</p></div><div><h3>Patients</h3><p>Thirteen patients with mild to moderate Crohn's disease were treated with enteric-release sodium butyrate tablets at a dosage of 4 g/day for eight weeks.</p></div><div><h3>Methods</h3><p>Before and after treatment, patients underwent coloscopy with evaluation of the clinical activity of their disease, systemic inflammation index and mucosal expression of interleukin (IL)-1β, IL-6, IL-12, interferon (IFN)-γ, tumour necrosis factor (TNF)-α and nuclear factor (NF)-κB.</p></div><div><h3>Results</h3><p>Of the nine patients (69%) responding to treatment, 7 (53%) exhibited complete response and 2 exhibited partial response. Endoscopic and histological evaluation scores were significantly improved (<em>p</em> < 0.05) and significant reductions were seen after treatment in white cell count, erythrocyte sedimentation rate (ESR), mucosal concentrations of NF-κB and IL-1β (<em>p</em> < 0.05).</p></div><div><h3>Conclusions</h3><p>Oral administration of butyrate may be effective in inducing clinical improvement or remission in patients with Crohn's disease.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60009-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77594577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome 丁酸盐治疗腹泻型肠易激综合征的疗效观察

Digestive and Liver Disease Supplements Pub Date : 2007-09-01 DOI: 10.1016/S1594-5804(08)60006-6

E. Scarpellini, E.C. Lauritano, A. Lupascu, C. Petruzzellis, M.L. Novi, D. Roccarina, M. Gabrielli, M. Serricchio, G. Gasbarrini, A. Gasbarrini

{"title":"Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome","authors":"E. Scarpellini, E.C. Lauritano, A. Lupascu, C. Petruzzellis, M.L. Novi, D. Roccarina, M. Gabrielli, M. Serricchio, G. Gasbarrini, A. Gasbarrini","doi":"10.1016/S1594-5804(08)60006-6","DOIUrl":"10.1016/S1594-5804(08)60006-6","url":null,"abstract":"<div><h3>Introduction</h3><p>Short-chain fatty acids affect enterocyte metabolism and differentiation. Butyric acid in particular is already used in ulcerative rectal colitis, pouchitis and antibiotic-induced diarrhoea.</p></div><div><h3>Aims</h3><p>To assess the efficacy of butyrate in the treatment of irritable bowel syndrome (IBS).</p></div><div><h3>Patients</h3><p>Fifty patients with IBS were treated using enteric-coated sodium butyrate tablets at a dosage of 1 g/day for 30 days.</p></div><div><h3>Methods</h3><p>The patients were divided into two subgroups: constipation-predominant IBS and diarrhoea-predominant IBS. The IBS variant and symptom scores of patients were recorded before and after treatment.</p></div><div><h3>Results</h3><p>Treatment with butyric acid reduced in normalisation of status in 68% and 71% of patients in the diarrhoea-predominant IBS group vs. 14% and 16% of patients in the constipation-predominant IBS group (respectively for the intent-to-treat and per-protocol analyses) (p < 0.005). The symptoms score for abdominal pain, meteorism and flatulence was significantly improved in patients with the diarrhoea variant compared with those with the constipation variant (p < 0.05).</p></div><div><h3>Conclusions</h3><p>Oral administration of butyrate may be effective in regulating status and improving gastrointestinal symptoms in patients with the diarrhoea-predominant irritable bowel syndrome.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60006-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88264913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Butyrate in the treatment of experimental models of colitis 丁酸盐对实验性结肠炎模型的治疗作用

Digestive and Liver Disease Supplements Pub Date : 2007-09-01 DOI: 10.1016/S1594-5804(08)60005-4

G. D'Argenio, G. Mazzone, N. Caporaso

引用次数: 1

首页上一页